NIH
-
Spying on shape-shifting enzyme
New molecular views of an enzyme may inform therapies for neurological, psychiatric or cardiac diseases. Read MoreMarch 18, 2011
-
Smell test tells disorders apart
Patients with certain autonomic nervous system disorders have impaired odor identification, which could aid in diagnosis. Read MoreMarch 17, 2011
-
New laser technique opens doors for drug discovery
A new laser technique can measure interactions between proteins tangled in a cell's membrane and a variety of other biological molecules: extremely difficult measurements that can aid the process of drug discovery. Read MoreMarch 14, 2011
-
Neuroscience drug discovery center opens at Vanderbilt
Vanderbilt University Medical Center has established a new Center for Neuroscience Drug Discovery to accelerate research that may lead to new treatments for Parkinson's disease, schizophrenia and other disorders of the brain. Read MoreMarch 11, 2011
-
Enzyme protects against inflamed colon
Increasing an enzyme required for a type of colon tissue may help dampen inflammation, a known risk factor for colon cancer. Read MoreMarch 7, 2011
-
Chasing Foxd3’s role in stem cells
Researchers use genetic manipulations in mice and single-cell analyses to help explain stem cell regulation. Read MoreMarch 4, 2011
-
Worm gene function? Check the map.
New gene expression atlas created for roundworms provides a basis for establishing roles for individual genes in the development of specific cell types. Read MoreMarch 3, 2011
-
A better picture of bone strength
A component of some MRI scans reveals that "soft" components, like collagen and collagen-bound water, are important players in bone strength. Read MoreMarch 2, 2011
-
New model to test how antidepressants work
A new mouse model offers the ability to better test how selective serotonin reuptake inhibitors (SSRIs) work and could lead to the development of new classes of anti-depressants. Read MoreFebruary 18, 2011
-
Vanderbilt-pioneered fetal surgery procedure yields positive results
Results of a landmark, seven-year National Institutes of Health-funded trial, Management of Myelomeningocele Study (MOMS), demonstrate clear benefit for babies who undergo fetal surgery to treat spina bifida, the most common birth defect in the central nervous system. Read MoreFebruary 9, 2011